Steven Xanthoudakis joins the CQDM
September 6, 2017
|Steven Xanthoudakis Appointed Chief Business Development Officer at CQDM|
STEVEN XANTHOUDAKIS APPOINTED CHIEF BUSINESS DEVELOPMENT OFFICER AT CQDM
MONTREAL (Quebec) September 6, 2017 — We are pleased to announce the appointment of Steven Xanthoudakis as our new Chief Business Development Officer. “Steve has extensive experience as a Scientist and Business Development professional in the pharma industry. His skill set in establishing multiple academic and biotech collaborations will enhance the way in which the CQDM engages in building new public-private partnerships”, stated Richard Fajzel, Chairman of the CQDM’s Board of Directors. “On behalf of the Board, I look forward to working with Steve and supporting him in this new role”.
Dr. Xanthoudakis has more than 25 years of professional experience in the biopharmaceutical industry. Since 2007, he held the position of Director of Global Business Development & Licensing for Merck Research Laboratories. His primary role in this position was to build lasting relationships with the venture capital, biotechnology and academic research communities in Canada and to help foster numerous partnering opportunities, including licensing deals and research collaborations.
As Chief Business Development Officer, Steven Xanthoudakis will be responsible to help build and execute the CQDM’s evolving business development strategy in Quebec and Canada. His professional record demonstrates that he has a strong ability to identify and consolidate global pharma support for innovative technology sourced across the continuum of both Canadian academic and biotech research.
“Few people are as familiar with the pharmaceutical industry as Steve. He has a great wealth of knowledge, an extensive network of contacts and a remarkable breadth of experience”, noted Diane Gosselin, CQDM’s President and Chief Executive Officer. “Given his previous experience with the pharmaceutical industry, his scientific background and knowledge of the Canadian research landscape, he is the ideal candidate for this newly created position”.
“I am extremely pleased to be joining CQDM in its important mission to help Canadian companies and research institutes translate their inventions into globally competitive innovative technologies that will have significant impact as new therapies or as enabling technology to support drug development”, mentioned Steven Xanthoudakis.
Since its inception in 2008, CQDM, a non-profit biopharmaceutical research consortium and an industrial research cluster, has been driven by the mission to fund projects which accelerate the development of drugs. It does so in conjunction with its partners in the pharmaceutical industry, the same companies which contributed to its creation.
CQDM is a catalyst where academia, governments and the life sciences industry converge to create practical solutions to complex medical challenges.
CQDM is funded by its industrial and pharmaceutical members as well as the Quebec government’s Ministry of Economy, Science and Innovation (MESI) and the Canadian government’s Business-Led Networks of Centres of Excellence (BL-NCE).